<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594552</url>
  </required_header>
  <id_info>
    <org_study_id>HR16-17 4081</org_study_id>
    <nct_id>NCT03594552</nct_id>
  </id_info>
  <brief_title>Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)</brief_title>
  <official_title>Modulation of the Brain Excitatory/Inhibitory (E/I) Balance Through Neuronal and Glial Systems in Autism Spectrum Disorder (ASD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the brain response to a single acute dose of Arbaclofen, the
      R-enantiomer of the GABA-B agonist Baclofen, compared to a single dose of placebo in healthy
      men with and without autism spectrum disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous research suggests that GABAergic drug compounds could shift brain excitation and
      inhibition (E-I) in the healthy brain and in neurodevelopmental psychiatric conditions, such
      as autism spectrum disorder (ASD) - where this balance is disrupted. A study by Ajram et al.
      (2017) has shown an E-I shifted towards more GABA in individuals with ASD, and not in
      controls, after a single dose of the anti-glutamatergic and pro-GABAergic drug Riluzole.
      Moreover, brain connectivity patterns in ASD patients where shifted towards the ones observed
      in the control group. However, it was unclear whether this changes could be driven by GABA
      receptors, thus more specific probes may help to clarify the mechanism underlying the E-I
      coordination in ASD. Therefore, this study will use neuroimaging and electrophysiology to
      investigate the brain E-I coordination in ASD compared to control participants when the
      system is responding to a single dose of the specific GABA-B (STX209) receptor agonist. 50
      adult individuals with ASD and 50 neurotypical adults (25 males and 25 females per group)
      will be invited to participate. Each participant will receive a single dose of the drug (15mg
      or 30mg Arbaclofen) or matched placebo). Brain activity and neurochemistry will be
      investigated using magnetic resonance imaging. Further data will be collected through
      questionnaires, behavioural tasks, blood samples, and sensory tasks using
      electroencephalography and retinal imaging.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">February 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Repeated-measures cross-over study, where each subject received each one of the three pharmacological probes in separate visits (i.e., placebo, arbaclofen low dose and arbaclofen high dose), with the order of tablet administration being pseudorandomized.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and investigators were blinded to the drug condition</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Neurochemical response to GABAergic stimulation.</measure>
    <time_frame>Through study completion, an average of 2 years.</time_frame>
    <description>Comparing brain excitation-inhibition measures (i.e., glutamate and GABA) when the GABAergic system is activated by a single oral dose of the GABA-B drug Arbaclofen versus the placebo condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional connectivity measures using resting state functional magnetic resonance imaging.</measure>
    <time_frame>Through study completion, an average of 2 years.</time_frame>
    <description>Maps of functional connectivity will be obtained for each condition and compared between adults with and without ASD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain oscillations under sensory stimulation</measure>
    <time_frame>Through study completion, an average of 2 years.</time_frame>
    <description>Brain oscillations and event-related potentials will be recorded during sensory stimulation using high density electroencephalography.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo, Arbaclofen_15, Arbaclofen_30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Arbaclofen_30, Arbaclofen_15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arbaclofen_30, Placebo, Arbaclofen_15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arbaclofen_15, Placebo, Arbaclofen_30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arbaclofen_15, Arbaclofen_30, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arbaclofen_30, Arbaclofen_15, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen_15</intervention_name>
    <description>Single oral dose (15mg)</description>
    <arm_group_label>Arbaclofen_15, Arbaclofen_30, Placebo</arm_group_label>
    <arm_group_label>Arbaclofen_15, Placebo, Arbaclofen_30</arm_group_label>
    <arm_group_label>Arbaclofen_30, Arbaclofen_15, Placebo</arm_group_label>
    <arm_group_label>Arbaclofen_30, Placebo, Arbaclofen_15</arm_group_label>
    <arm_group_label>Placebo, Arbaclofen_15, Arbaclofen_30</arm_group_label>
    <arm_group_label>Placebo, Arbaclofen_30, Arbaclofen_15</arm_group_label>
    <other_name>r-baclofen, STX209</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen_30</intervention_name>
    <description>Single oral dose (30mg)</description>
    <arm_group_label>Arbaclofen_15, Arbaclofen_30, Placebo</arm_group_label>
    <arm_group_label>Arbaclofen_15, Placebo, Arbaclofen_30</arm_group_label>
    <arm_group_label>Arbaclofen_30, Arbaclofen_15, Placebo</arm_group_label>
    <arm_group_label>Arbaclofen_30, Placebo, Arbaclofen_15</arm_group_label>
    <arm_group_label>Placebo, Arbaclofen_15, Arbaclofen_30</arm_group_label>
    <arm_group_label>Placebo, Arbaclofen_30, Arbaclofen_15</arm_group_label>
    <other_name>r-baclofen, STX209</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral dose placebo (oral tablet)</description>
    <arm_group_label>Arbaclofen_15, Arbaclofen_30, Placebo</arm_group_label>
    <arm_group_label>Arbaclofen_15, Placebo, Arbaclofen_30</arm_group_label>
    <arm_group_label>Arbaclofen_30, Arbaclofen_15, Placebo</arm_group_label>
    <arm_group_label>Arbaclofen_30, Placebo, Arbaclofen_15</arm_group_label>
    <arm_group_label>Placebo, Arbaclofen_15, Arbaclofen_30</arm_group_label>
    <arm_group_label>Placebo, Arbaclofen_30, Arbaclofen_15</arm_group_label>
    <other_name>Placebo oral tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASD participants must pass diagnostic threshold for ASD on the Autism Diagnostic
             Interview-Revised (if and informant is available)

          -  ASD participants must be currently symptomatic on Autism Diagnostic Observation
             Schedule (ADOS)

          -  Age 18-60 years

          -  Can give informed consent

          -  medication free in the month preceding participation; but regular medication (used in
             a stable dose over the two months previous to participation) with drug which does not
             affect glutamate or GABA directly may be permitted

          -  IQ&gt;70

        Exclusion Criteria:

          -  IQ&lt;70

          -  history of psychosis, co-morbid major mental illness, significant physical illness
             (heart disease, high blood pressure, seizures) habitual substance misuse (including
             alcohol)

          -  ASD caused by a known genetic syndrome e.g. Fragile X or 22q11 deletion syndrome,

          -  past/present treatment for epilepsy

          -  Women will be excluded from this pilot study to reduce heterogeneity in a small
             sample; avoid the issues around exposing women of reproductive age to a drug; and
             because pregnancy is a routine exclusion criteria for research MRI. Lastly, ASD is
             more common in men.

          -  Change of medication dose/start of a new pharmacological therapy in the month prior to
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grainne McAlonan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grainne McAlonan, PhD</last_name>
    <phone>02078480831</phone>
    <email>grainne.mcalonan@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eileen Daly, PhD</last_name>
    <phone>02078480700</phone>
    <email>eileen.daly@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gr√°inne McAlonan, PhD</last_name>
      <phone>02078480831</phone>
      <email>grainne.mcalonan@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Dr Grainne McAlonan</investigator_full_name>
    <investigator_title>Deputy head of department</investigator_title>
  </responsible_party>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Arbaclofen</keyword>
  <keyword>E-I balance</keyword>
  <keyword>pharmacological imaging</keyword>
  <keyword>GABA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

